XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. - Wikidata - wikimedia - TriplyDB

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

http://www.wikidata.org/entity/Q33429923

about

FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis.Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer.New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.

P2860

Q33722816-2B17C37C-04A5-4E0D-ACDA-F33ACAEF3522 Q36345346-CD32D551-F8A5-48B2-89FE-C87B0297E0A2 Q50041173-562264ED-6BAA-450B-A36B-413DC01E2C57 Q54990524-1E75993C-CF27-408D-8F22-7E930BB98948 Q55367746-D8C419A9-982E-45AD-8969-F90A962E4045

P2860

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

http://www.wikidata.org/entity/Q33429923

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

@ast

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

@en

type

label

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

@ast

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

@en

prefLabel

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

@ast

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

@en

P1433

Q33429923-2965C3C1-D07E-436C-9D2E-6F05703A4F8D

P1476

Q33429923-80CD1D36-D721-4E72-ABF0-2577D1032382

P2093

Q33429923-4190862C-9912-46B4-9A8C-94FAD420F48A

Q33429923-75FB9079-2E12-4A21-BC11-F9D568CC8F33

Q33429923-88F9DF2F-A3B7-4803-90FE-D4C57BC3B4AE

Q33429923-97DFD582-C1BD-4C33-8238-A3B6B6401E98

Q33429923-A38C0420-32C4-4E49-9DF2-F262D31DAE1B

P2860

Q33429923-01BD1E87-AEED-4398-B18A-A146A8AC6854

Q33429923-1175801C-E6BE-41A8-97E3-B32CA921A387

Q33429923-208B9719-52A9-415E-96CF-21CB6E184856

Q33429923-39EBF265-9A10-4B6D-9A8F-BB59CB496093

Q33429923-45DB0BE1-5FCC-4F19-A366-067C16AF24EC

Q33429923-79677792-D419-4171-88B7-3F7972F3C1CB

Q33429923-8653238D-EAAC-40AD-B90C-120D65ABEC12

Q33429923-8B7F5C37-5D5F-43A0-8B0D-75078AD2FDD1

Q33429923-8D92A723-6CEF-4384-9AF5-F90F3944E081

Q33429923-926F2889-D917-46F2-87F6-ABFB6E88C418

P304

Q33429923-4E07850A-E557-4E30-85BF-10B8D697A849

P31

Q33429923-10029c29-7824-4973-a0a4-381ed2dfb7b2

Q33429923-7DA4A9B0-F3B2-474A-935C-C92C522EB020

P356

Q33429923-080DF1DA-CC43-4FAF-9A5F-3068BBE65B97

P433

Q33429923-D7263A31-13F9-4C8B-AB71-F4AE3B48DFB6

P478

Q33429923-2B446C2B-CE21-4D8C-9281-803129BE0863

P577

Q33429923-266CF390-98B4-45E8-BA5D-17357F2609EF

P698

Q33429923-C07CA78A-4740-4BCC-B095-2FEA1ABC3C7E

P921

Q33429923-26D0198F-BA39-4586-AA7C-81BF7BD7E29C

P356

07357907.2015.1104689

P1433

Cancer Investigation

P1476

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

@en

P2093

Bing-Hong Xiong

http://www.w3.org/2001/XMLSchema#string

Li Ma

http://www.w3.org/2001/XMLSchema#string

Tao Zhang

http://www.w3.org/2001/XMLSchema#string

Yong Cheng

http://www.w3.org/2001/XMLSchema#string

Yu Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Cancer statistics, 2005

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.

Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis.

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.

Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.

P304

94-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/07357907.2015.1104689

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26864862

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer